At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Axvitiy Ax3 accelorometer (device)
- How long the study runs
- Study runs about 19 months (dates as stated)
- About the drug or intervention
- Axvitiy Ax3 accelorometer — device: Participants will wear the accelometer for 2 months
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 80
- Started
- 2026-02-17
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for mds (myelodysplastic syndrome)
- • Clinical study - 80 participants
- • Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with mds (myelodysplastic syndrome)
Where?
- • Oxford - Oxford University Hospitals NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia. This can cause severe fatigue, shortness of breath and brain fog and may need regular blood transfusions. Their quality of life (QoL) is often very poor during treatment because of these side effects, and it is hard to deal with. Doctors use blood tests to decide whether a patient is well enough for treatment and when to start treatment. However, blood tests do not tell us how a person feels, and it is not the same in everyone. We need a better way for doctors to monitor patients' QoL and these symptoms so that they are physically and emotionally able to continue their treatment. It is hard for doctors to accurately assess this through speaking to their patients and doctors do not record or discuss these effects of treatment very well with patients. The aim of this study is to better understand how people feel during their treatment and how we can best use blood transfusions to maintain QoL. 80 adult patients who are starting blood cancer treatments will be asked to answer questionnaires about how they are feeling and their symptoms during their treatment. Participants will be asked to wear a smartwatch to measure their physical activity levels. Activity data collected will then be compared with their reported QoL and blood counts to help us understand when patients can tolerate difficult treatments the best and how blood transfusions affect this. Patients, their family and carers will be invited to take part in an interview to understand their views on how we can improve their care, QoL and access to transfusions. A better understanding of the impact of low blood counts on QoL can help us use blood transfusions to benefit patients' lives. This work will better match transfusions to individual peoples' needs and therefore 'personalise' blood transfusion care.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Patients aged ≥18 years with WHO-defined MDS or mixed myeloproliferative/myelodysplastic tumour overlap syndromes...
- ✓Intention to undertake disease modifying treatment
- ✓Life expectancy ≥ 6 months
- ✓Able to complete quality of life questionnaires
- ✓Willing and able to provide agreement to take part for participation in the study
Who cannot take part
- ✗Poor performance/functional status (activity scale system ECOG ≥3)
- ✗Participants with known arrhythmias or other significant cardiological conductivity disorders
- ✗Patients with severe other health conditions
- ✗Patients with known skin allergies or conditions that in the opinion of the investigator would compromise the safety...
- ✗Hospitalised patients
See the full criteria
Where Is This Study? (1 UK site)
Oxford University Hospitals NHS Trust
Oxford OX39DU, United Kingdom
How to Get in Touch
Matthew H Poynton, MBBS
Sponsor contactCONTACT